Overview of EGFR-Mutant Advanced NSCLC
Panelists discuss how advanced EGFR-mutant non-small cell lung cancer (NSCLC) requires careful molecular testing and staging for optimal targeted therapy selection, with particular attention to patient demographics and presentation patterns.
Video content above is prompted by the following:
- Please provide a brief overview of advanced EGFR-mutant NSCLC
- How might a typical patient present with advanced EGFR-mutant NSCLC?
- What are the key risk factors? (age, gender, family history, other demographics)
- What steps do you take to diagnose, risk assess, and stage your patients with advanced EGFR-mutant NSCLC?
Recent Videos
Related Content
